Faculty Disclosures
| Fatta B. Nahab, MD, FAAN |
Dr. Nahab has received personal compensation for serving as an employee of Neuron23. Dr. Nahab has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Encora. Dr. Nahab has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for ActualSignal. Dr. Nahab has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Attune Neurosciences, Inc.. Dr. Nahab has stock in Biogen. Dr. Nahab has received personal compensation in the range of $500-$4,999 for serving as a DSMB Member with NIH. |
| Theresa A. Zesiewicz, MD |
Dr. Zesiewicz has received personal compensation for serving as an employee of Medscape. Dr. Zesiewicz has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Lexeo. Dr. Zesiewicz has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Steminent. Dr. Zesiewicz has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Larimar. Dr. Zesiewicz has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biohaven. Dr. Zesiewicz has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. Zesiewicz has received intellectual property interests from a discovery or technology relating to health care. Dr. Zesiewicz has received intellectual property interests from a discovery or technology relating to health care. Dr. Zesiewicz has received intellectual property interests from a discovery or technology relating to health care. |
| Samuel A. Frank, MD, FAAN |
Dr. Frank has received personal compensation in the range of $500-$4,999 for serving as a Consultant for uniQure. Dr. Frank has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Teva. Dr. Frank has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche. The institution of Dr. Frank has received research support from Huntington's Disease Society of America. The institution of Dr. Frank has received research support from Roche/Genentech. The institution of Dr. Frank has received research support from CHDI Foundation. The institution of Dr. Frank has received research support from Huntington Study Group. The institution of Dr. Frank has received research support from Cerevel. |
| Vicki L. Wheelock, MD |
Dr. Wheelock has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche Pharmaceuticals. Dr. Wheelock has received personal compensation in the range of $500-$4,999 for serving as a Consultant for uniQure. Dr. Wheelock has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for PRIME Continuing Medical 好色先生. |
| Victor W. Sung, MD |
Dr. Sung has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Teva Neuroscience. Dr. Sung has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Genentech. Dr. Sung has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Neurocrine. Dr. Sung has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for UniQure. |
| Sarah Janicki, MD |
No disclosure on file
|
| James A. Brunberg, MD |
No disclosure on file
|
|
No disclosure on file
|
| Tiago Mestre, MD, MSC |
Dr. Mestre has received personal compensation in the range of $500-$4,999 for serving as a Consultant for CHDI. Dr. Mestre has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for PTC. Dr. Mestre has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Abbvie. Dr. Mestre has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Ipsen. Dr. Mestre has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Abbvie. Dr. Mestre has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Abbvie. The institution of Dr. Mestre has received research support from CIHR. The institution of Dr. Mestre has received research support from Ontario Research Fund. The institution of Dr. Mestre has received research support from MJFF. The institution of Dr. Mestre has received research support from Parkinson Canada. The institution of Dr. Mestre has received research support from University of Ottawa/PRC. |
| Steven M. Hersch, MD, PhD |
Dr. Hersch has received personal compensation for serving as an employee of Eisai Inc.. Dr. Hersch has stock in Voyager Therapeutics. The institution of an immediate family member of Dr. Hersch has received research support from NIH. Dr. Hersch has received intellectual property interests from a discovery or technology relating to health care. |
| Claudia Testa, MD, PhD |
Dr. Testa has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Neurocrine. Dr. Testa has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for uniQure. Dr. Testa has received personal compensation in the range of $5,000-$9,999 for serving as an officer or member of the Board of Directors for Tremor Research Group. |
| Bernhard G. Landwehrmeyer, MD |
Dr. Landwehrmeyer has received personal compensation in the range of $500-$4,999 for serving as a Consultant for ACADIA PHARMACEUTICALS INC, San Diego, CA. Dr. Landwehrmeyer has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Lundbeck Valby, Denmark. Dr. Landwehrmeyer has received personal compensation in the range of $500-$4,999 for serving as a Consultant for AOP Orphan Pharmaceuticals AG, Vienna, Austria. Dr. Landwehrmeyer has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Remix Therapeutics, Inc., Cambridge, MA. Dr. Landwehrmeyer has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for HSG Clinical Research, Inc. Dr. Landwehrmeyer has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for F. Hoffmann-La Roche Ltd, Basel, Switzerland. Dr. Landwehrmeyer has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche Pharma AG, Grenzach/Whylen, Germany. Dr. Landwehrmeyer has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis Pharma AG, Basel, Switzerland. The institution of Dr. Landwehrmeyer has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis Pharma AG, Basel, Switzerland. Dr. Landwehrmeyer has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for PTC Therapeutics, Inc., South Plainfield, NJ . Dr. Landwehrmeyer has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Triplet Therapeutics, Inc. Cambridge, MA. Dr. Landwehrmeyer has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Takeda Pharma. Dr. Landwehrmeyer has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Roche Pharma AG, Grenzach/Whylen, Germany. Dr. Landwehrmeyer has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for F. Hoffmann-La Roche Ltd, Basel, Switzerland. Dr. Landwehrmeyer has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Novartis Pharma AG, Basel, Switzerland. The institution of Dr. Landwehrmeyer has received research support from CHDI Foundation. The institution of Dr. Landwehrmeyer has received research support from European Commission. The institution of Dr. Landwehrmeyer has received research support from German Federal Government BMBF. The institution of Dr. Landwehrmeyer has received research support from German Research Council DFG. Dr. Landwehrmeyer has received publishing royalties from a publication relating to health care. Dr. Landwehrmeyer has received publishing royalties from a publication relating to health care. |
| Esther Cubo Delgado, MD, PhD, FAAN |
Dr. Cubo Delgado has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Abbvie. Dr. Cubo Delgado has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Zambon. Dr. Cubo Delgado has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Abbvie. The institution of Dr. Cubo Delgado has received research support from Spanish health ministry. The institution of Dr. Cubo Delgado has received research support from European union grant. |
| Charles S. DeCarli, MD, FAAN |
Dr. DeCarli has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. The institution of Dr. DeCarli has received research support from NIH. |
| Daniel O. Claassen, MD, FAAN |
Dr. Claassen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Spark . The institution of Dr. Claassen has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for Alterity. Dr. Claassen has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for University of Michigan. Dr. Claassen has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for HD Insights. The institution of Dr. Claassen has received research support from NIH. The institution of Dr. Claassen has received research support from CHDI. The institution of Dr. Claassen has received research support from HDSA. The institution of Dr. Claassen has received research support from Department of Defense. The institution of Dr. Claassen has received research support from CHDI. The institution of Dr. Claassen has received research support from Genentech/ Roche. |
| Sarah Farias |
No disclosure on file
|
| Alexandra O. Duffy, MD, FAAN |
Dr. Duffy has nothing to disclose. |
| David A. Stamler, MD |
Dr. Stamler has received personal compensation for serving as an employee of Alterity Therapeutics. Dr. Stamler has stock in Alterity Therapeutics. |
| Cristina Sampaio, Prof |
No disclosure on file
|
| Saul Martinez-Horta |
No disclosure on file
|
| Cheryl Fitzer-Attas, PhD |
Dr. Fitzer-Attas has received personal compensation for serving as an employee of Sage Therapeutics. The institution of Dr. Fitzer-Attas has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Pharma Two B. The institution of Dr. Fitzer-Attas has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for Golden Heart Flower. The institution of Dr. Fitzer-Attas has received personal compensation in the range of $100,000-$499,999 for serving as a Consultant for Sage Therapeutics. Dr. Fitzer-Attas has stock in Golden Heart Flower. Dr. Fitzer-Attas has received intellectual property interests from a discovery or technology relating to health care. |
| Gerhard Bauer |
No disclosure on file
|
| Jan Nolta, PhD |
No disclosure on file
|
| Ashok J. Dayananthan, MD |
No disclosure on file
|
| Christina L. Vaughan, MD, MHS |
Dr. Vaughan has nothing to disclose. |